Elsevier Inc.

SHERPA: Unknown

People

  1. Lee
    Lee
  2. Giralt
    Giralt
  3. Mulhall
    Mulhall
  4. Perales
    Perales
  5. Yorke
    Yorke
  6. Wolden
    Wolden
  7. Rusch
    Rusch
  8. Yamada
    Yamada
  9. Zhang
    Zhang
  10. Travis
    Travis

Groups

  1. Department of Medicine (4218)
  2. Surgery (2710)
  3. Survivorship Research (2394)
  4. Solid Tumor Oncology Division (2240)
  5. Radiation Oncology, Department of (2047)
  6. GSK Faculty (1884)
  7. Center for Hematologic Malignancies (1669)
  8. Hematologic Malignancies, Division of (1531)
  9. Sloan Kettering Institute Faculty (1376)
  10. Medical Physics (1209)
Search Within
Formats
  1. Journal Article (6733)
  2. Meeting Abstract (4312)
  3. Review (631)
  4. Book Section (542)
  5. Editorial (253)
  6. Conference Paper (132)
  7. Correspondence (92)
  8. Guidelines (85)
  9. Research Letter (33)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4218)
  2. Surgery (2710)
  3. Survivorship Research (2394)
  4. Solid Tumor Oncology Division (2240)
  5. Radiation Oncology, Department of (2047)
  6. GSK Faculty (1884)

More Groups

People
  1. Nancy Lee (413)
  2. Michael Zelefsky (401)
  3. Sergio Giralt (386)
  4. John Mulhall (381)
  5. Miguel-Angel Perales (303)
  6. Andreas Rimner (292)

More People

Years
  1. 2026 (3)
  2. 2025 (397)
  3. 2024 (708)
  4. 2023 (680)
  5. 2022 (745)
  6. 2021 (665)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2629)
  2. Journal of Thoracic Oncology (973)
  3. Biology of Blood and Marrow Transplantation (815)
  4. European Journal of Cancer (529)
  5. Journal of Sexual Medicine (440)
  6. Clinical Lymphoma, Myeloma and Leukemia (402)

More Publications

Results (12842)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Increased WEE1 expression is predictive of short progression-free survival, independent of standard prognostic factors in multiple myeloma
    Meeting Abstract

    Simhal, A.; Firestone, R.; Oh, J. H.; Norton, L.; Usmani, S.; Deasy, J.; Maclachlan, K.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Patient-reported outcomes in the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel vs standard of care in patients with lenalidomide-refractory multiple myeloma after 1-3 lines of therapy
    Meeting Abstract

    Weisel, K.; Mina, R.; Mylin, A.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M.; Shune, L.; Isufi, I.; Harrison, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of COVID-19 on outcomes with teclistamab in the phase 1/2 MajesTEC-1 study in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Usmani, S.; Bahlis, N. J.; Costa, L.; Manteca, M. V. M.; Nooka, A.; Perrot, A.; Thaman, P.; Qi, K.; Uhlar, C.; Chastain, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • QUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of BMS-986393 in patients with quadruple-class exposed relapsed or refractory multiple myeloma
    Meeting Abstract

    Patel, K.; Nadeem, O.; Munshi, N.; Iida, S.; Mailankody, S.; Neri, P.; Gregory, T.; Piasecki, J.; Ziyad, S.; Hu, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and efficacy of talquetamab for patients with heavily pretreated relapsed-refractory multiple myeloma
    Meeting Abstract

    Shaikh, H.; Lochner, J.; Friend, R.; Snyder, J.; Davis, J.; Patrus, G.; Dileo, R.; Ahmed, N.; Mewawalla, P.; poonsombudlert, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Prompt and profound responses with talquetamab in patients with heavily pretreated relapsed-refractory multiple myeloma - Another bridging therapy
    Meeting Abstract

    Shaikh, H.; Lochner, J.; Davis, J.; Snyder, J.; Friend, R.; Patrus, G.; DiLeo, R.; Mushtaq, M. U.; Green, K.; Mewawalla, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save